Early antiretroviral therapy significantly reduced the risk of AIDS and HIV-related illness in a large study in low and middle-income countries, according to the final results of the HPTN 052 study published in Lancet Infectious Diseases.
Higher baseline viral load, longer time to viral suppression and low-level viraemia below the level of detection of standard tests raise the risk of viral rebound amongst people with HIV on antiretroviral therapy (ART), according to a pair of
People with HIV had higher mortality than HIV-negative individuals after hospitalisation for acute coronary syndrome, but the excess risk disappeared for people on antiretroviral therapy with high CD4 cell counts, researchers reported last week at the IDWeek 2013
Tenofovir alafenamide (TAF), a new formulation that produces higher drug levels in cells but allows for lower dosing, was as effective as the current tenofovir disoproxil fumarate (TDF) formulation, but had less impact on markers of kidney function and bone turnover, researchers reported yesterda
For people taking HIV therapy, a persistent detectable viral load at any level is associated with an increased risk of virologic failure, Canadian research published in the online edition of Clinical Infectious Diseases shows.
Nearly three-quarters of HIV/HCV co-infected patients in the French HEPAVIH cohort achieved end-of-treatment virological response to hepatitis C treatment with telaprevir plus pegylated interferon/ribavirin, even though one-third had potential contraindications to this type of therapy, according
The World Health Organization (WHO) Global Tuberculosis Report 2012 provides the latest information and analysis about the tuberculosis (TB) epidemic and progress in TB care and control at global, regional and country levels.